Regarding cervical cancer (CC), inhibition of IDO-1 (Navoximod) in combination with atezolizumab (PD-L1 inhibitor) has been studied in a phase 1 clinical trial (NCT02471846); however, antitumoral effectiveness was partial [36]. This evidence concerns the gene CD274 and cervical carcinoma.